Versant Capital Management’s Veracyte VCYT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$12.8K Buy
279
+18
+7% +$868 ﹤0.01% 2169
2026
Q2
$15.3K Sell
261
-33
-11% -$1.38K ﹤0.01% 2063
2026
Q1
$9.47K Buy
294
+192
+188% +$7.11K ﹤0.01% 2163
2025
Q4
$4.29K Hold
102
– – ﹤0.01% 2303
2025
Q3
$3.5K Sell
102
-12
-11% -$344 ﹤0.01% 2317
2025
Q2
$3.08K Sell
114
-816
-88% -$23.6K ﹤0.01% 2296
2025
Q1
$27.6K Buy
930
+862
+1,268% +$32.9K ﹤0.01% 1156
2024
Q4
$2.69K Hold
68
– – ﹤0.01% 1986
2024
Q3
$2.32K Hold
68
– – ﹤0.01% 1527
2024
Q2
$1.47K Buy
+68
New +$1.43K ﹤0.01% 1590
2023
Q4
– Sell
-54
Closed -$1.21K – 2020
2023
Q3
$1.21K Sell
54
-21
-28% -$540 ﹤0.01% 1477
2023
Q2
$1.91K Buy
+75
New +$1.82K ﹤0.01% 1387

Other funds holding VCYT

Versant Capital Management's VCYT Position: Q3 2026 in Review

Versant Capital Management increased its Veracyte (VCYT) stake by 6.9% in Q3 2026, buying an estimated $868 and bringing the position to 279 shares worth $12.8K. The position accounts for ﹤0.01% of the portfolio, ranked #2169.

Versant Capital Management first reported a position in VCYT in Q2 2023 and has held it in 12 quarters since. The position peaked at $27.6K in Q1 2025. 383 funds tracked by Wall St. Rank hold VCYT as of Q3 2026.

  • Versant Capital Management held 279 shares of Veracyte worth $12.8K as of Q3 2026.
  • Versant Capital Management bought 18 Veracyte shares in Q3 2026, an estimated $868.
  • Veracyte made up ﹤0.01% of Versant Capital Management's portfolio in Q3 2026, its #2169 holding.
  • Versant Capital Management first reported a position in Veracyte in Q2 2023 and has held it in 12 quarters since.
  • Versant Capital Management's Veracyte position peaked at $27.6K in Q1 2025.
  • 383 funds tracked by Wall St. Rank held Veracyte as of Q3 2026.

Based on Versant Capital Management's 13F filing for Q3 2026, filed 2 Oct 2026.